Diabetes drug semaglutide may shield blood vessels from hidden damage

NCT ID NCT07314684

Recruiting now Disease control Sponsor: Federico II University Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated Jun 17, 2026 · Updated 20 times

Summary

This study looks at whether adding semaglutide to standard diabetes care can reduce inflammation and improve blood vessel function in people with type 2 diabetes who have a high risk of heart disease but no major heart or blood vessel problems yet. About 80 adults will be randomly assigned to receive semaglutide plus usual care or usual care alone for one year. Researchers will measure changes in blood markers of inflammation and vessel health at 26 and 52 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Azienda Ospedaliera Sant'Anna e San Sebastiano
RECRUITING

Caserta, Caserta, 81100, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••
Federico II University
RECRUITING

Naples, Napoli, 80131, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

T2DM (TYPE 2 DIABETES MELLITUS) T2DM (TYPE 2 DIABETES MELLITUS)